Clinical trials: Pancreatic Adenocarcinoma Locally Advanced
Pancreatic Cancer
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced…
- Trial name
- NCT00059982
- Testing
- perifosine
- Where
- 10 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Extrahepatic Bile Duct Cancer, Pancreatic Cancer
Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00010088
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 50 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of 3-AP when given together with radiation therapy in treating patients with stage III pancreatic cancer that cannot be removed by surgery.
- Trial name
- NCT00288093
- Testing
- 3-Dimensional Conformal Radiation Therapy, Triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasm
Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer
This is a randomized, multicenter, phase II study of with nab-paclitaxel plus gemcitabine or gemcitabine alone for the treatment of chemotherapy-naïve patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT03807999
- Testing
- Nab-paclitaxel, Gemcitabine
- Volunteers
- 125 people
- Sponsor
- Hacettepe University
Pancreatic Adenocarcinoma
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with…
- Trial name
- NCT04926467
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor Research Institute
Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease
- Trial name
- DUAL-NK-PDAC (NCT07627711)
- Testing
- EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Locally Advanced Unresectable Pancreatic Adenocarcinoma
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
- Trial name
- CA209-9KH (NCT04098432)
- Testing
- Nivolumab, Stereotactic radiotherapy
- Where
- 4 sites in Czechia
- Volunteers
- 15 people
- Sponsor
- University Hospital Hradec Kralove
Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
This phase II trial studies how well liposomal irinotecan, leucovorin, and fluorouracil work in treating patients with high grade neuroendocrine cancer of gastrointestinal, unknown, or pancreatic origin that does not respond to…
- Conditions
- Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT03736720
- Testing
- Fluorouracil, Leucovorin, Liposomal Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Adenocarcinoma Non-resectable
A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma.
- Trial name
- NCT01677962
- Testing
- Poly-ICLC, dendritic cell
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced…
- Trial name
- NCT06261359
- Testing
- CEND-1, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Adenocarcinoma
Portal Vein Thrombosis Associated With Unresectable Pancreatic Cancers : a Prospective Multicentric Cohort Study
Little is known concerning the management of portal vein thrombosis (PVT) in digestive cancers other than hepato-cellular carcinoma (HCC).
- Trial name
- THROMPAN (NCT04814251)
- Testing
- Observationnal cohort
- Volunteers
- 200 people
- Sponsor
- Poitiers University Hospital
Pancreatic Adenocarcinoma
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
This study is a prospective, open-label, randomized controlled trial that enrolled previously untreated patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT06789679
- Testing
- Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
This clinical trial tests the safety, side effects, best dose and feasibility of using 64Cu-DOTA A2 scFv-Fc2 DM with positron emission tomography for the imaging of patients with PSCA-expressing pancreatic cancer that has spread…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT07608627
- Testing
- Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
This study intends to explore conversion therapy for locally advanced pancreatic cancer (LAPC). The intervention starts with modified stereotactic body radiation therapy (3-day regimen), followed by systemic therapy within 1-2…
- Trial name
- NCT07827053
- Testing
- Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT
- Volunteers
- 36 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT04046887
- Testing
- Lonsurf, Gemcitabine, Nab-Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Advanced Solid Tumors Cancer
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics…
- Trial name
- NCT03821935
- Testing
- Livmoniplimab, Budigalimab
- Where
- 64 sites in United States, Australia and 12 more
- Volunteers
- 364 people
- Sponsor
- AbbVie
Pancreatic Cancer
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
This Phase Ib dose escalation study will evaluate BTH1704, a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1, and Imprime PGG, a glucan contained in yeast that is essential in triggering a…
- Trial name
- PM-01 (NCT02132403)
- Testing
- BTH1704, IMPRIME PGG, Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois Chicago
Pancreatic Cancer
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.
- Trial name
- NCT03704662
- Testing
- Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Medical College of Wisconsin
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05365581
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 46 sites in United States, China and 6 more
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust